Comparative Pharmacology
Head-to-head clinical analysis: GRANIX versus NEULASTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRANIX versus NEULASTA.
GRANIX vs NEULASTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Granix (tbo-filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) analog that binds to G-CSF receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
Pegfilgrastim is a recombinant methionyl human granulocyte colony-stimulating factor (G-CSF) conjugated to polyethylene glycol. It binds to G-CSF receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
5 μg/kg subcutaneously once daily for up to 7 days, or 5 μg/kg subcutaneously once daily for up to 14 days for stem cell mobilization.
6 mg subcutaneously once per chemotherapy cycle, administered at least 24 hours after cytotoxic chemotherapy and at least 14 days before next cycle.
None Documented
None Documented
Terminal half-life approximately 3.5 hours (range 1.8–5.4 h) in healthy subjects; clearance increases with neutrophil recovery due to G-CSF receptor-mediated uptake.
Terminal elimination half-life is approximately 15-23 hours (mean ~18 hours) in healthy subjects, allowing for once-per-cycle dosing for chemotherapy-induced neutropenia.
Primarily renal excretion; neutrophil-mediated clearance. <1% unchanged in urine.
Primarily renal clearance (through glomerular filtration and proteolytic degradation). Approximately 80% of the dose is eliminated renally as degraded peptides.
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor